6:02 PM
 | 
Dec 13, 2012
 |  BC Extra  |  Clinical News

Lilly discontinues Phase III RA trial of tabalumab

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase III FLEX-M trial of tabalumab ( LY2127399) for rheumatoid arthritis after the compound...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >